Table 1.
Baseline clinical as well as biochemical characteristics of study groups.
| Median and range | Healthy control (N = 15) | DC w/o sepsis (N = 62) | DC with sepsis (N = 72) | p-Value in betweenw/o and with sepsis |
|---|---|---|---|---|
| Age | 32 (20–40) | 48 (22–62) | 44 (29–60) | 0.07 |
| Male:female | 11:4 | 54:8 | 70:2 | – |
| Total bilirubin (mg/dl) | 1 (0.3–1.5) | 4.5 (1.6–24) | 14.5 (2.2–31.7) | 0.00 |
| AST (IU/ml) | 20 (5–40) | 59.75 (31–510) | 114 (31–1037) | 0.05 |
| ALT (IU/ml) | 25 (10–40) | 34.5 (20–634) | 41.5 (11–233) | 1.00 |
| INR (s) | 1 (0.8–1.2) | 1.66 (1.1–3.3) | 2.58 (1.58–6.75) | 0.00 |
| PCT (ng/ml) | 0.8 (0.2–2) | 0.42 (0.04–3.25) | 8.4 (0.07–88.4) | 0.03 |
| Lactate (mmol/L) | 1.5 (1–2) | 1.4 (0.6–5.2) | 2.1 (0.2–13.3) | 0.02 |
| Sodium (mmol/L) | 140 (136–145) | 133 (124.3–142.7) | 131 (113.2–148.4) | 1.00 |
| Creatinine (mg/ml) | 0.6 (0.2–1) | 0.86 (0.3–2.9) | 1.3 (0.3–5.18) | 0.04 |
| MELD Na | 8 (6–10) | 23 (10–37) | 32.5 (14–40) | 0.00 |
| SIRS criteria | ||||
| TLC (109 L) | 6 (4–11) | 6.3 (3.1–19.8) | 12.65 (2.7–43.6) | 0.00 |
| Pulse (/min) | 70 (60–100) | 84 (60–110) | 94 (62–132) | 0.00 |
| RR (/min) | 14 (12–16) | 20 (16–24) | 22 (14–34) | 0.02 |
| Temperature (F) | 98 (97–99) | 98.2 (97–98.9) | 98.4 (96–100) | 1.00 |
| Differential leukocyte count | ||||
| Neutrophils (%) | 60 (40–75) | 70 (59–89) | 81 (36–95) | 0.00 |
| Lymphocytes (%) | 30 (20–45) | 16 (3.4–36) | 8 (1–29) | 0.00 |
| Monocytes (%) | 5 (2–10) | 11 (2–18) | 8 (2–30) | 0.03 |
DC, decompensated cirrhosis; AST, aspartate aminotransferase; ALT, alanine aminotransferase; INR, international normalized ratio; PCT, procalcitonin; MELD Na, model for end-stage liver diseases-sodium; SIRS, systemic inflammatory response syndrome; TLC, total leukocyte count; RR, respiratory rate.